{"id":"epirubicin-or-doxorubicin-cyclophosphamide-paclitaxel","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-80","effect":"Nausea and vomiting"},{"rate":"60-90","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"30-60","effect":"Peripheral neuropathy (paclitaxel-related)"},{"rate":"5-20","effect":"Cardiotoxicity (anthracycline-related)"},{"rate":"50-70","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin and doxorubicin are anthracycline antibiotics that intercalate into DNA and inhibit topoisomerase II, preventing DNA replication and transcription. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Paclitaxel is a taxane that stabilizes microtubules and prevents cell division. Together, this sequential combination (often called EC-T or AC-T regimen) targets multiple mechanisms of cell proliferation.","oneSentence":"This is a chemotherapy regimen combining anthracyclines (epirubicin or doxorubicin) and cyclophosphamide followed by paclitaxel, which work by intercalating DNA and disrupting microtubule formation to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:41.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early-stage breast cancer (neoadjuvant or adjuvant treatment)"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06144944","phase":"PHASE3","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-17","conditions":"Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma","enrollment":160},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT06611813","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-11","conditions":"HR+/HER2- Breast Cancer","enrollment":30},{"nctId":"NCT05862064","phase":"PHASE3","title":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":606},{"nctId":"NCT06914440","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-06-05","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT02455141","phase":"PHASE3","title":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-03","conditions":"Breast Neoplasm","enrollment":786},{"nctId":"NCT06977893","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-24","conditions":"HR+/HER2- Breast Cancer","enrollment":194},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT06768931","phase":"PHASE2","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-30","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer","enrollment":192},{"nctId":"NCT05296746","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-05-03","conditions":"Breast Cancer Stage II","enrollment":1100},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT03356860","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.","status":"COMPLETED","sponsor":"Grand Hôpital de Charleroi","startDate":"2017-04-13","conditions":"Breast Cancer, Triple Negative Breast Cancer, Luminal B","enrollment":57},{"nctId":"NCT03498716","phase":"PHASE3","title":"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-02","conditions":"Triple Negative Breast Cancer","enrollment":2199},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT06121570","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05981014","phase":"PHASE1, PHASE2","title":"Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-08-01","conditions":"Breast Neoplasms","enrollment":196},{"nctId":"NCT05763992","phase":"PHASE2","title":"Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-05-15","conditions":"Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure","enrollment":145},{"nctId":"NCT00129922","phase":"PHASE3","title":"Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-11","conditions":"Breast Cancer","enrollment":1289},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT04771871","phase":"PHASE2","title":"MicroRNA Profiles in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"University College Hospital, Ibadan","startDate":"2021-11-29","conditions":"Triple Negative Breast Cancer","enrollment":42},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03894007","phase":"PHASE2","title":"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","status":"TERMINATED","sponsor":"Renske Altena","startDate":"2019-05-23","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer","enrollment":6},{"nctId":"NCT01593020","phase":"PHASE2","title":"Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-03","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02909751","phase":"PHASE2","title":"Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-09-14","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03983538","phase":"","title":"Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2015-06-02","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT03289819","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC","status":"COMPLETED","sponsor":"Institut fuer Frauengesundheit","startDate":"2018-03-23","conditions":"Malignant Neoplasm of Breast","enrollment":53},{"nctId":"NCT02682693","phase":"PHASE2","title":"Denosumab as an add-on Neoadjuvant Treatment (GeparX)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2017-02-13","conditions":"Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II","enrollment":780},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":"Breast Cancer","enrollment":2104},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55},{"nctId":"NCT02789332","phase":"PHASE2","title":"Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2016-09","conditions":"Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms","enrollment":107},{"nctId":"NCT04301739","phase":"PHASE3","title":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2020-04-17","conditions":"Triple Negative Breast Cancer","enrollment":522},{"nctId":"NCT04127019","phase":"PHASE3","title":"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":"Primary Breast Cancer","enrollment":2079},{"nctId":"NCT03876886","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-02-22","conditions":"Triple Negative Breast Cancer","enrollment":200},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00559845","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT03273595","phase":"PHASE2","title":"Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-07","conditions":"Neoplasms, Breast","enrollment":100},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT01205217","phase":"PHASE2","title":"Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Neoplasms, Breast","enrollment":""},{"nctId":"NCT02365805","phase":"PHASE2","title":"Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-04","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT02838225","phase":"PHASE2","title":"DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2009-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00429299","phase":"PHASE2","title":"Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08","conditions":"Neoplasms, Breast","enrollment":121},{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720},{"nctId":"NCT01594177","phase":"PHASE2","title":"Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-05","conditions":"Unilateral HER2 Positive Breast Cancer","enrollment":65},{"nctId":"NCT00005581","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2000-06","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT00011921","phase":"PHASE3","title":"Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"EBMT Solid Tumors Working Party","startDate":"1997-09","conditions":"Lung Cancer","enrollment":430},{"nctId":"NCT00070278","phase":"PHASE3","title":"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2005-01","conditions":"Breast Cancer","enrollment":800},{"nctId":"NCT00629278","phase":"PHASE3","title":"Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2007-12","conditions":"Breast Cancer","enrollment":2500},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00311636","phase":"PHASE3","title":"Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"Gruppo Italiano Mammella (GIM)","startDate":"2003-09","conditions":"Breast Cancer","enrollment":280},{"nctId":"NCT00072319","phase":"PHASE2","title":"Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-08","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01159236","phase":"NA","title":"Molecular Triaging of Newly Diagnosed Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00336791","phase":"PHASE3","title":"Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Breast Cancer","enrollment":273},{"nctId":"NCT01378533","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-05","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00140075","phase":"PHASE3","title":"Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2000-11","conditions":"Adenocarcinoma","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8513,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin or doxorubicin, cyclophosphamide, paclitaxel","genericName":"Epirubicin or doxorubicin, cyclophosphamide, paclitaxel","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a chemotherapy regimen combining anthracyclines (epirubicin or doxorubicin) and cyclophosphamide followed by paclitaxel, which work by intercalating DNA and disrupting microtubule formation to kill rapidly dividing cancer cells. Used for Early-stage breast cancer (neoadjuvant or adjuvant treatment), Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}